ABL1 and acute lymphoblastic leukemia: Asciminib (formerly ABL001), a potent and selective allosteric ABL1 inhibitor, is undergoing clinical development testing in patients with CML and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).